March has been an incredible month for CervoMed Inc. (CRVO), with its share price skyrocketing by 350%.
This clinical-stage company is focused on developing treatments for age-related neurologic disorders and its lead asset is Neflamapimod, a specific inhibitor of an enzyme called p38 alpha kinase, which is involved in inflammation and cellular stress responses.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com